Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation
Boomi™, the intelligent integration and automation leader, today announced that the six inaugural Boomi AI Agents recently unveiled at the company’s Boomi World event will be available in the Boomi Enterprise Platform as part of existing customer licenses, enabling customers to fully harness AI-powered capabilities for unparalleled innovation. These agents include:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611275117/en/
Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation (Graphic: Business Wire)
- Boomi Answers: Save time spent searching through user community discussions and articles. Simply ask questions about Boomi and get the most useful answer from over 240K community users.
- Boomi DataDetective: Stay on top of data privacy, protect sensitive information with AI-powered data classification, and track where data is being moved.
- Boomi DesignGen: Ask GenAI to design integration processes based on 200M+ common patterns and best practices.
- Boomi GPT: Describe integration and automation needs using natural language and have conversations with the Boomi Enterprise Platform to get more meaningful results, faster.
- Boomi Pathfinder: Provide patented suggestions on the next best steps to take when building integration processes.
- Boomi Scribe: Skip manually writing documentation about existing and AI-generated integration processes, and let GenAI handle the busywork of detailing process descriptions and business use cases.
To accelerate innovation, Boomi recently introduced the Boomi AI Agent Framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.
“AI agents are revolutionizing industries by automating repetitive tasks, analyzing vast datasets, and offering personalized customer service,” said Steve Lucas, CEO at Boomi. “Data is the lifeblood of AI, especially with pre-trained transformers and LLM's. Boomi delivers that data, and the Boomi AI Agents improve efficiency, accuracy, and scalability for organizations by operating around the clock with high precision, enhancing decision-making, supporting human workers, and driving innovation. These capabilities lead to increased productivity and cost savings, making them invaluable assets for organizations to maintain a competitive edge."
AI agents are sophisticated software entities designed with a specific scope and personality, enabling them to function within predefined parameters and exhibit particular behaviors. Operating autonomously, they can make decisions using advanced AI-based reasoning algorithms, and can independently take actions to achieve their objectives. AI agents can function with or without human intervention. Additionally, AI agents can either work independently or collaborate with other AI agents, depending on the requirements of the task at hand. This flexibility and autonomy make AI agents highly versatile and capable of performing a wide range of functions across various applications, improving decision-making processes with data-driven insights, and powering innovation by enabling new applications and services.
The Boomi AI Agent Framework includes three types of agents running on the Boomi Enterprise Platform:
Boomi AI Agents
Boomi AI Agents provide AI-powered capabilities within the platform. These capabilities can be utilized through the Boomi GPT conversational user interface (CUI), via specialized GUI, in the process canvas, or via API.
Partner AI Agents
Partner AI agents are pluggable components that allow Boomi Enterprise Platform users to install and use best-of-breed AI functions from Boomi’s network of partners. These agents can be utilized in the same way as Boomi AI Agents, and allow rich capabilities to be incorporated from across the digital ecosystem. An example is the recently announced Boomi FinTalk powered by Vianai agent that allows business users to get detailed responses on financial information via Boomi GPT.
User-created AI Agents
User-created AI agents are developed using the Boomi Enterprise Platform, which provides all the necessary building blocks. Boomi’s connectivity and orchestration capabilities enable users to interact with selected models via API, access proprietary data sources, and automate actions through various applications. The Boomi platform’s process canvas allows the creation of sophisticated workflows to retrieve, combine, filter, and contextualize data, facilitating model prompting and techniques like RAG and fine-tuning. Boomi DataHub serves as an access point and repository for the agents’ knowledge base, while Boomi Flow and Boomi API Management offer human or machine interfaces to package these components into standalone AI agents.
Boomi AI Agents will be available with the July 2024 release of the Boomi Enterprise Platform. More information can be found here.
Additional Resources
- Read up on the latest blog posts from the Boomi leadership team
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611275117/en/
Contacts
Media
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom